ÐÓ°ÉÔ­´´

Orbis Medicines, based in Copenhagen, is gaining attention in the biotech sector with its innovative oral macrocycle drug discovery platform. By developing oral medications, Orbis aims to address gaps in current treatment options, which often rely on injectables or less effective oral drugs. This approach targets unmet medical needs and seeks to improve patient comfort and compliance. Their novel delivery mechanisms differentiate them in a competitive market. Backed by investors like Novo A/S and Forbion Capital Partners, Orbis has the support needed to advance its technologies and bring transformative treatments to market.